Living definition
What is GSK Jideytro (zidesamtinib)?
Drug Discovery & Development Bio, Health & Neuro
- As of
- 2026-08-20
- Revision
- 2026-08-17.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
GSK Jideytro (zidesamtinib) is a targeted small-molecule kinase inhibitor for cancers driven by a specific oncogenic fusion, designed to remain active against the resistance mutations that limit earlier inhibitors of the same target.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-08-20, verified readiness is 88 (claimed 100, reported 97, gap 12) — Critical evidence strength; current signals suggest Track; not yet.
The readiness fact belongs to the canonical Readiness Verdict for GSK Jideytro (zidesamtinib).
Dataset approval
Human editorial release
pragma.vision editorial — standing authorization (operator dev@soft.house, 2026-07-17)
- Dataset
- 2026-08-17.1
- Hash
- sha256:0c37108a182f510fc8cf4d1dfc3a30339f2b59e62654201edea2f530a268707e
- Approved
- 2026-08-17